Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA grants orphan drug status to H3 Biomedicine’s cancer treatment H3B-8800

pharmaceutical-technologyAugust 17, 2017

Tag: H3 Biomedicine , Orphan Drug , AML

PharmaSources Customer Service